跳至主要内容
临床试验/NCT02482883
NCT02482883已完成不适用

Evaluation of the Efficacy of Transcutaneous Trigeminal Nerve Stimulation for Prevention of Cerebral Vasospasm and Its Consequences After Subarachnoid Haemorrhage Due to Ruptured Aneurysm: a Multicentre, Randomized, Double-blind Study

Poitiers University Hospital2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2015年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Development of cerebral Infarction on MRI (FLAIR sequence)

研究概览

简要总结

Subarachnoid haemorrhage (SAH) secondary to ruptured aneurysm represents 5 to 15% of all cases of stroke. The mortality rate of SAH is 40% and the risk of serious neurological sequelae among survivors is 10 to 20%.The causes of morbidity and mortality are mainly related to the initial damage induced by SAH and delayed cerebral ischaemia (DCI), which is generally secondary to cerebral vasospasm.

Cerebral vasospasm is one of the main factors of poor prognosis after SAH, as it is associated with a 1.5- to 3-fold increase in the mortality rate during the 2 weeks following SAH in these patients.

Despite a significant improvement in the time to management of this disease and the fact that the ruptured aneurysm is very often rapidly excluded by surgical or endovascular intervention, patients who survive the initial SAH remain at risk of severe complications over the following 2 weeks.

Vascular stenosis of an arterial segment, called cerebral vasospasm, is observed in more than 70 to 95% of cases on digital subtraction angiography between the 7th and 14th days after ruptured aneurysm. This angiographic vasospasm can be responsible for cerebral infarction in 52 to 81% of cases.

Despite 50 years of research, no clearly demonstrated effective treatment for vasospasm is currently available.

This is a multicentre, randomized, comparative study, including 364 patients during the acute phase following ruptured aneurysm, in whom management is very often limited to control of complications, after exclusion of the aneurysm.

The objective of this study is to validate the efficacy of transcutaneous trigeminal nerve stimulation for the prevention of vasospasm and limitation of the consequences of delayed cerebral ischaemia after SAH.

This is an innovative project, as it comprises intervention in these patients prior to the development of complications and could limit the development of these complications. The prevention tool, based on external facial nerve stimulation, is a totally innovative, reversible and noninvasive technique. Use of nerve stimulation in this indication has never been previously reported and could radically modify the intensive care management of this disease over the years to come.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years and ≤ 75 years.
  • Admission within 48 h after onset of SAH.
  • Ruptured cerebral aneurysm confirmed on CT angiography or cerebral angiography.
  • Patient classified as grade I-IV according to the WFNS (World Federation of Neurological Surgeons) classification.
  • Covered by French national health insurance.
  • Absence of active cancer.

排除标准

  • Age < 18 years and > 75 years.
  • Absence of signature of the informed consent form by the patient or a close relative.
  • Person subject to reinforced protection Clinical state on admission classified as WFNS grade V (excessively high mortality rate).
  • Intracerebral or intraventricular haemorrhage without subarachnoid involvement.
  • Major complication during the aneurysm exclusion procedure.
  • SAH with no demonstrated aneurysm.
  • Presence of non-ruptured cerebral aneurysm.
  • Contraindication to placement of a transcutaneous device.

结局指标

主要结局

Development of cerebral Infarction on MRI (FLAIR sequence)

时间窗: At 3 months

次要结局

  • Evaluation of quality of life (EQ-5D)(At 6 months)
  • An anomaly of perfusion detected on perfusion CT-scan(At day 6)
  • Evaluation of MTT (Mean Transit Time)(At day 6)
  • Functional disability (modified Rankin scale and GOS).(At 6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验